Mangini Siobhan Nolan - Jul 1, 2022 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
President and CFO
Signature
/s/ Valerie Pierce, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Jul 1, 2022
Transactions value $
$0
Form type
4
Date filed
7/1/2022, 06:36 PM
Previous filing
Mar 4, 2022
Next filing
Mar 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +100K $0.00 100K Jul 1, 2022 Common Stock 100K $12.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option vest over a four-year period measured from from July 1, 2022, with 1/48th of the shares vesting on a monthly basis, subject to the reporting person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan) as of each such vesting date.